IntegraGen becomes First Certified French Service Provider for Illumina GoldenGate and Infinium Genotyping
News Jun 18, 2007
Concurrent with the annual European Human Genetics Conference in Nice, France, Illumina, Inc. has announced that IntegraGen SA has received Illumina Certified Service Provider (CSPro™) certification for GoldenGate® and Infinium® genotyping technologies.
Illumina is a developer, manufacturer, and marketer of next-generation life science tools and integrated systems for the analysis of genetic variation and biological function. The GoldenGate assay is Illumina's first array-based platform that combines high-sample throughput, high multiplexing, and single-site CpG resolution for DNA methylation profiling.
The Infinium Whole-Genome Genotyping BeadArray™ solution offers single or multi-sample BeadChip formats and high-density architecture with the flexibility to add additional custom SNP Assays.
"IntegraGen is a company dedicated to offering high-quality services to other research institutes, either private or academic, and is the first laboratory in France to achieve CSPro certification for GoldenGate and Infinium Genotyping," said Karen Possemato, Illumina's Director of Corporate Marketing. "By becoming a member of CSPro, they have further demonstrated their commitment to the life science community, providing delivery of the highest-quality data available for genetic analysis applications."
Emmanuel Martin, IntegraGen's Director of Services and Arrays, said: "IntegraGen is proud of its ability to leverage core competencies and provide genetic services to the research community. Receiving Illumina CSPro certification is an endorsement of both Illumina and IntegraGen's commitment to quality, and provides our customers with even greater confidence in our ability meet their needs."
Instead of searching for a needle in a haystack, what if you were able to sweep the entire haystack to one side, leaving only the needle behind? That's the strategy researchers followed in developing a new microfluidic device that separates elusive circulating tumor cells (CTCs) from a sample of whole blood.READ MORE